Systemic Juvenile Idiopathic Arthritis Market Report 2026

Systemic Juvenile Idiopathic Arthritis Market Overview

• Systemic Juvenile Idiopathic Arthritis market size has reached to $1.36 billion in 2025 • Expected to grow to $1.8 billion in 2030 at a compound annual growth rate (CAGR) of 5.6% • Growth Driver: The Increasing Prevalence Of Autoimmune Disorders Driving The Growth Of The Market Due To Genetic Susceptibility And Immune System Dysregulation • Market Trend: New Intravenous Therapy Expands Treatment Options With Enhanced Access And Flexibility • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Systemic Juvenile Idiopathic Arthritis Market?

Systemic juvenile idiopathic arthritis (SJIA) is a rare type of childhood arthritis that causes inflammation throughout the body, not just in the joints. It is characterized by persistent high fevers, rash, and swelling or pain in multiple joints. Unlike other forms of juvenile arthritis, SJIA also affects internal organs such as the liver, spleen, and heart. The exact cause is unknown, but it is believed to involve an abnormal immune system response. The main treatment types of systemic juvenile idiopathic arthritis are drug treatment, biologics, and other treatment types. Drug treatment refers to the use of medications, such as biologics, corticosteroids, and disease-modifying antirheumatic drugs (DMARDs), to reduce inflammation, control symptoms, and prevent joint damage in patients with sJIA. It is used across various age groups, including infants, children, and adolescents. These treatments are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by various end-users, including hospitals, specialty clinics, academic research centers, and others.

What Is The Systemic Juvenile Idiopathic Arthritis Market Growth Forecast?

The systemic juvenile idiopathic arthritis market size is expected to see strong growth in the next few years. It will grow to $1.8 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing investments in pediatric autoimmune research, rising adoption of interleukin-targeted therapies, expansion of clinical trials for rare diseases, growing focus on personalized medicine, increasing access to specialty pediatric care. Major trends in the forecast period include increasing adoption of targeted biologic therapies, rising focus on early and accurate sjia diagnosis, growing use of personalized treatment protocols, expansion of clinical research in pediatric rheumatology, enhanced monitoring of disease progression.

Global Systemic Juvenile Idiopathic Arthritis Market Segmentation

1) By Treatment Type: Drug Treatment, Biologics, Other Treatment Types 2) By Age Group: Infants, Children, Adolescents 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By End-User: Hospitals, Specialty Clinics, Academic Research Centers, Other End-Users Subsegments: 1) By Drug Treatment: Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Disease-Modifying Antirheumatic Drugs 2) By Biologics: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Tumor Necrosis Factor Inhibitors 3) By Other Treatment Types: Physical Therapy, Occupational Therapy, Supportive Care, Experimental Therapies

What Is The Driver Of The Systemic Juvenile Idiopathic Arthritis Market?

The increasing prevalence of autoimmune disorders is expected to propel the growth of the systemic juvenile idiopathic arthritis market going forward. Autoimmune disorders refer to conditions in which the body's immune system mistakenly attacks its own healthy cells, tissues, or organs. The increasing prevalence of autoimmune disorders is primarily due to genetic susceptibility, as inherited genes can predispose individuals to abnormal immune responses that mistakenly target the body’s own tissues. Systemic juvenile idiopathic arthritis is a distinct type of autoimmune disease that offers valuable insights into the mechanisms of immune system dysregulation and the inflammatory pathways that drive disease progression. By studying SJIA, researchers gain a deeper understanding of how abnormal immune responses contribute to widespread inflammation and tissue damage characteristic of autoimmune disorders. For instance, in February 2024, according to Arthritis Australia, an Australia-based non-profit organization, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA), with the numbers expected to rise by 2040 to approximately 280,040 males and 479,828 females. Therefore, the increasing prevalence of autoimmune disorders is driving the growth of the systemic juvenile idiopathic arthritis industry.

Key Players In The Global Systemic Juvenile Idiopathic Arthritis Market

Major companies operating in the systemic juvenile idiopathic arthritis market are Johnson And Johnson, F. Hoffmann-La Roche Limited, Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly And Company, Takeda Pharmaceutical Company Limited, Amgen Incorporated, Boehringer Ingelheim, Regeneron Pharmaceuticals Incorporated, Chugai Pharmaceutical Company Limited, Genentech Incorporated, Swedish Orphan Biovitrum Aktiebolag, Zydus Lifesciences Limited, Celltrion Incorporated, Mycenax Biotech Incorporated.

Global Systemic Juvenile Idiopathic Arthritis Market Trends and Insights

Major companies operating in the systemic juvenile idiopathic arthritis market are focusing on developing innovative products, such as intravenous formulations, to improve efficacy, safety, and patient compliance. Intravenous formulations are medications prepared to be administered directly into a vein, allowing the drug to quickly enter the bloodstream for rapid and controlled therapeutic effects. For instance, in October 2025, Celltrion Inc., a South Korea-based biopharmaceutical company, introduced AVTOZMA, a tocilizumab biosimilar intravenous formulation, in the United States. This biosimilar serves as an alternative to the reference product Actemra and has received regulatory approval for multiple indications, including systemic juvenile idiopathic arthritis (sJIA), rheumatoid arthritis, and cytokine release syndrome. The introduction of AVTOZMA is anticipated to significantly enhance patient access to advanced therapies by providing a cost-effective treatment option while maintaining comparable safety, efficacy, and quality standards to the originator drug. By offering both intravenous and subcutaneous formulations, AVTOZMA affords clinicians greater flexibility in tailoring treatment regimens to meet the diverse needs of individual patients, thereby optimizing therapeutic outcomes across various clinical settings.

What Are Latest Mergers And Acquisitions In The Systemic Juvenile Idiopathic Arthritis Market?

In April 2025, Organon & Co., a US-based pharmaceutical company, acquired Tofidence (tocilizumab-bavi), a biosimilar to ACTEMRA injection, from Biogen for an undisclosed amount. With this acquisition, Organon aimed to strengthen and expand its U.S. immunology or biosimilars portfolio by gaining a multi indication arthritis treatment. Biogen Inc. is a US-based biotechnology company that provides a treatment for systemic juvenile idiopathic arthritis.

Regional Outlook

North America was the largest region in the systemic juvenile idiopathic arthritis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Systemic Juvenile Idiopathic Arthritis Market?

The systemic juvenile idiopathic arthritis market consists of revenues earned by entities by providing services such as pharmaceutical treatments, clinical consultation services, hospital and outpatient care, diagnostic services, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The systemic juvenile idiopathic arthritis market also includes sales of canakinumab, tocilizumab, methotrexate, corticosteroids, and nonsteroidal anti-inflammatory drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Systemic Juvenile Idiopathic Arthritis Market Report 2026?

The systemic juvenile idiopathic arthritis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the systemic juvenile idiopathic arthritis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.